Brooks Laboratories Ltd

Brooks Laboratories Ltd

₹ 148 1.79%
12 Dec 1:16 p.m.
About

Incorporated in 2002, Brooks Laboratories Ltd is a pharmaceutical company working on contract basis catering to the critical care segment[1]

Key Points

Business Overview:[1]
BLL is an EU GMP & ISO 9001:2008 certified manufacturer and marketer of pharmaceutical formulations

  • Market Cap 387 Cr.
  • Current Price 148
  • High / Low 186 / 72.5
  • Stock P/E
  • Book Value 22.6
  • Dividend Yield 0.00 %
  • ROCE -24.7 %
  • ROE -28.1 %
  • Face Value 10.0

Pros

Cons

  • Stock is trading at 6.47 times its book value
  • Company has low interest coverage ratio.
  • Company has a low return on equity of -22.3% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
21.46 19.01 28.46 17.12 18.08 15.30 12.61 15.70 24.32 21.75 17.72 17.93 20.79
25.74 25.39 32.37 25.72 27.30 23.85 16.31 19.61 25.42 25.12 27.25 19.85 24.20
Operating Profit -4.28 -6.38 -3.91 -8.60 -9.22 -8.55 -3.70 -3.91 -1.10 -3.37 -9.53 -1.92 -3.41
OPM % -19.94% -33.56% -13.74% -50.23% -51.00% -55.88% -29.34% -24.90% -4.52% -15.49% -53.78% -10.71% -16.40%
0.11 0.37 0.18 0.03 0.40 0.45 0.03 0.05 0.09 0.16 0.65 0.07 0.20
Interest 0.75 0.74 0.84 0.62 0.63 0.75 0.18 0.17 0.19 0.21 0.27 0.16 0.32
Depreciation 1.74 1.88 1.95 1.98 2.28 2.33 0.44 0.44 0.44 0.43 0.46 0.40 0.43
Profit before tax -6.66 -8.63 -6.52 -11.17 -11.73 -11.18 -4.29 -4.47 -1.64 -3.85 -9.61 -2.41 -3.96
Tax % -27.33% -14.25% -8.90% -15.85% -32.82% -15.21% 0.00% 0.00% 0.00% 0.78% 0.00% 0.00% 0.00%
-4.83 -7.40 -5.93 -9.40 -7.87 -9.48 -4.29 -4.47 -1.64 -3.88 -9.61 -2.41 -3.96
EPS in Rs -1.84 -2.52 -1.37 -2.63 -1.79 -1.92 -1.64 -1.71 -0.62 -1.48 -3.66 -0.92 -1.51
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
77 91 63 79 78
77 105 93 97 96
Operating Profit 1 -14 -30 -18 -18
OPM % 1% -16% -47% -23% -23%
1 1 1 1 1
Interest 3 3 2 1 1
Depreciation 7 7 7 2 2
Profit before tax -9 -24 -38 -20 -20
Tax % 115% -19% -19% 0%
-19 -19 -31 -20 -20
EPS in Rs -7.40 -4.31 -7.97 -7.46 -7.57
Dividend Payout % 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 1%
TTM: 15%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 0%
TTM: -27%
Stock Price CAGR
10 Years: 15%
5 Years: 46%
3 Years: 8%
1 Year: 25%
Return on Equity
10 Years: %
5 Years: %
3 Years: -22%
Last Year: -28%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 25 25 25 26 26
Reserves 54 63 49 39 33
31 25 7 6 9
52 83 29 19 23
Total Liabilities 162 196 110 90 91
108 110 15 14 15
CWIP 1 15 0 0 0
Investments 0 0 64 43 36
54 71 31 34 41
Total Assets 162 196 110 90 91

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024
4 -37 -14 -10
-5 -25 0 0
1 64 11 10
Net Cash Flow 0 2 -3 0

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 65 71 74 75
Inventory Days 178 157 80 60
Days Payable 233 159 165 97
Cash Conversion Cycle 9 68 -12 38
Working Capital Days -5 95 -3 58
ROCE % -16% -30% -25%

Shareholding Pattern

Numbers in percentages

14 Recently
Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
66.41% 66.41% 66.41% 66.41% 66.41% 66.41% 66.41% 63.59% 63.59% 63.59% 63.59% 63.59%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.46% 3.86% 3.86% 3.86% 3.86%
33.59% 33.59% 33.59% 33.58% 33.59% 33.59% 33.58% 33.94% 32.56% 32.55% 32.55% 32.53%
No. of Shareholders 10,91611,14511,10410,52410,41010,70911,21610,68610,02811,43211,54311,282

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents